References

1. Adams R, Popplewell AG, Rapecki SE. (2008) Antibody molecules which bind il-17a and il-17f. Patent number: WO2008047134. Assignee: Ucb Pharma S.A.. Priority date: 18/10/2006. Publication date: 24/04/2008.

2. Allan A, Chow C-K , Liu L, Lu J, Tetreault JW. (2010) Interleukin specific monoclonal antibody for use in treatment and prevention of autoimmune, cell proliferative, inflammatory and developmental disorders. Patent number: US7838638. Assignee: Eli Lilly And Company. Priority date: 13/12/2005. Publication date: 23/11/2010.

3. Allan B, Benschop RJ, Lu J. (2013) Anti-baff-anti-il-17 bispecific antibodies. Patent number: WO2013158577A1. Assignee: Eli Lilly. Priority date: 20/04/2012. Publication date: 24/10/2013.

4. Andrews MD, Dack KN, de Groot MJ, Lambert M, Sennbro CJ, Larsen M, Stahlhut M. (2022) Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein-Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases. J Med Chem, 65 (13): 8828-8842. [PMID:35767390]

5. Bruniquel D, Chavalet L, Chvatchko Y, Kilkman JA, Leger O, Proudfoot AEI, Rommelaere H, Saunders MJS, Union A, Vicari A. (2012) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same. Patent number: WO2012156219A1. Assignee: Ablynx Nv, Merck Patent Gmbh. Priority date: 05/05/2011. Publication date: 22/11/2012.

6. Cai Y, Fleming C, Yan J. (2013) Dermal γδ T cells--a new player in the pathogenesis of psoriasis. Int Immunopharmacol, 16 (3): 388-91. [PMID:23499509]

7. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J et al.. (2011) Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity, 35 (4): 596-610. [PMID:21982596]

8. Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, Poorbaugh J, Schmitz C, Wang E, Woodman ME. (2024) Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study. Clin Pharmacol Ther, [Epub ahead of print]. [PMID:38294091]

9. Di Padova FE, Gram H, Hofstetter H, Jeschke M, Rondeau J-M, Van Den Berg W. (2010) IL-17 antagonistic antibodies. Patent number: US7807155. Assignee: Novartis Ag. Priority date: 05/08/2004. Publication date: 05/10/2010.

10. Ganesan R, Rasool M. (2017) Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis. Mol Immunol, 91: 134-144. [PMID:28898718]

11. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A. (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol, 129 (9): 2175-83. [PMID:19295614]

12. Ishibashi N, Watanabe T, Kanehira M, Watanabe Y, Hoshikawa Y, Notsuda H, Noda M, Sakurada A, Ohkouchi S, Kondo T et al.. (2018) Bone marrow mesenchymal stromal cells protect allograft lung transplants from acute rejection via the PD-L1/IL-17A axis. Surg Today, 48 (7): 726-734. [PMID:29546496]

13. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol, 187 (1): 490-500. [PMID:21606249]

14. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB. (2013) The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol, 133 (1): 17-26. [PMID:22673731]

15. Onishi RM, Gaffen SL. (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology, 129 (3): 311-21. [PMID:20409152]

16. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q et al.. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6 (11): 1133-41. [PMID:16200068]

17. Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W et al.. (2016) Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs, 8 (1): 141-9. [PMID:26390837]

18. Zhang L, Liu J, Cao G, Sun P. (2015) Il-17a conjugate and uses thereof. Patent number: WO2015070697. Assignee: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.. Priority date: 18/11/2013. Publication date: 21/05/2015.

19. Zhu S, Qian Y. (2012) IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci, 122 (11): 487-511. [PMID:22324470]